HDACs and HDAC Inhibitors in Cancer Development and Therapy

被引：890

作者：

Li, Yixuan ^{[1
]}

Seto, Edward ^{[1
]}

机构：

[1] George Washington Univ, Ctr Canc, Dept Biochem & Mol Med, Washington, DC 20037 USA

来源：

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2016年 / 6卷 / 10期

基金：

美国国家卫生研究院;

关键词：

HISTONE DEACETYLASE INHIBITOR; HUMAN BREAST-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEPATOCELLULAR-CARCINOMA; ACUTE MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; DNA-DAMAGE RESPONSE; PHASE-I; POOR-PROGNOSIS; BIOLOGICAL EVALUATION;

D O I：

10.1101/cshperspect.a026831

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture. Histone acetylation, a well-studied post-translational histone modification, is controlled by the opposing activities of histone acetyl-transferases (HATs) and histone deacetylases (HDACs). By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biological processes including cancer initiation and progression. This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.

引用

页数：34

共 268 条

[1] Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma [J].

Adams, Heiner ;

Fritzsche, Florian R. ;

Dirnhofer, Stephan ;

Kristiansen, Glen ;

Tzankov, Alexandar .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (06) :577-584

[2] Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer [J].

Aghdassi, Ali ;

Sendler, Matthias ;

Guenther, Annett ;

Mayerle, Julia ;

Behn, Claas-Olsen ;

Heidecke, Claus-Dieter ;

Friess, Helmut ;

Buechler, Markus ;

Evert, Matthias ;

Lerch, Markus M. ;

Weiss, Frank Ulrich .

GUT, 2012, 61 (03) :439-448

[3] Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells [J].

Ahn, Mee-Young ;

Ahn, Ji-Wee ;

Kim, Hyung-Sik ;

Lee, Jun ;

Yoon, Jung-Hoon .

ONCOLOGY REPORTS, 2015, 33 (04) :1899-1907

[4] Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine [J].

Ahrens, Theresa D. ;

Timme, Sylvia ;

Hoeppner, Jens ;

Ostendorp, Jenny ;

Hembach, Sina ;

Follo, Marie ;

Hopt, Ulrich T. ;

Werner, Martin ;

Busch, Hauke ;

Boerries, Melanie ;

Lassmann, Silke .

EPIGENETICS, 2015, 10 (05) :431-445

[5] Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells [J].

Aldana-Masangkay, Grace I. ;

Rodriguez-Gonzalez, Agustin ;

Lin, Tara ;

Ikeda, Alan K. ;

Hsieh, Yao-Te ;

Kim, Yong-Mi ;

Lomenick, Brett ;

Okemoto, Kazuo ;

Landaw, Elliot M. ;

Wang, Dongpeng ;

Mazitschek, Ralph ;

Bradner, James E. ;

Sakamoto, Kathleen M. .

LEUKEMIA & LYMPHOMA, 2011, 52 (08) :1544-1555

[6] Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma [J].

Amengual, Jennifer E. ;

Johannet, Paul ;

Lombardo, Maximilian ;

Zullo, Kelly ;

Hoehn, Daniela ;

Bhagat, Govind ;

Scotto, Luigi ;

Jirau-Serrano, Xavier ;

Radeski, Dejan ;

Heinen, Jennifer ;

Jiang, Hongfeng ;

Cremers, Serge ;

Zhang, Yuan ;

Jones, Simon ;

O'Connor, Owen A. .

CLINICAL CANCER RESEARCH, 2015, 21 (20) :4663-4675

[7] P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells [J].

Bajbouj, K. ;

Mawrin, C. ;

Hartig, R. ;

Schulze-Luehrmann, J. ;

Wilisch-Neumann, A. ;

Roessner, A. ;

Schneider-Stock, R. .

JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (03) :503-516

[8] A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas [J].

Balasubramanian, S. ;

Ramos, J. ;

Luo, W. ;

Sirisawad, M. ;

Verner, E. ;

Buggy, J. J. .

LEUKEMIA, 2008, 22 (05) :1026-1034

[9] A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors [J].

Banerji, Udai ;

van Doorn, Leni ;

Papadatos-Pastos, Dionysis ;

Kristeleit, Rebecca ;

Debnam, Phillip ;

Tall, Matthew ;

Stewart, Adam ;

Raynaud, Florence ;

Garrett, Michelle Dawn ;

Toal, Martin ;

Hooftman, Leon ;

De Bono, Johann Sebastian ;

Verweij, Jaap ;

Eskens, Ferry A. L. M. .

CLINICAL CANCER RESEARCH, 2012, 18 (09) :2687-2694

[10] Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP [J].

Bangert, A. ;

Cristofanon, S. ;

Eckhardt, I. ;

Abhari, B. A. ;

Kolodziej, S. ;

Haecker, S. ;

Vellanki, S. H. K. ;

Lausen, J. ;

Debatin, K-M ;

Fulda, S. .

ONCOGENE, 2012, 31 (44) :4677-4688

← 1 2 3 4 5 6 7 8 9 10 →